7.0693
price down icon0.14%   -0.0207
 
loading
전일 마감가:
$7.09
열려 있는:
$7.05
하루 거래량:
7,098
Relative Volume:
0.07
시가총액:
$32.70M
수익:
-
순이익/손실:
$-31.11M
주가수익비율:
-4.6205
EPS:
-1.53
순현금흐름:
$-28.18M
1주 성능:
+4.42%
1개월 성능:
+14.56%
6개월 성능:
-35.24%
1년 성능:
-74.90%
1일 변동 폭
Value
$7.05
$7.1792
1주일 범위
Value
$6.6287
$7.25
52주 변동 폭
Value
$5.3495
$30.03

Tempest Therapeutics Inc Stock (TPST) Company Profile

Name
명칭
Tempest Therapeutics Inc
Name
전화
415-798-8589
Name
주소
2000 SIERRA POINT PARKWAY, BRISBANE
Name
직원
5
Name
트위터
Name
다음 수익 날짜
2025-03-26
Name
최신 SEC 제출 서류
Name
TPST's Discussions on Twitter

TPST을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
TPST
Tempest Therapeutics Inc
7.05 32.70M 0 -31.11M -28.18M -1.53
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
443.91 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
527.38 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
317.21 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
558.21 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
243.52 28.51B 3.81B -644.79M -669.77M -6.24

Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-04-10 다운그레이드 H.C. Wainwright Buy → Neutral
2025-04-10 다운그레이드 Scotiabank Sector Outperform → Sector Perform
2024-03-14 개시 Scotiabank Sector Outperform
2024-02-08 개시 Jefferies Buy

Tempest Therapeutics Inc 주식(TPST)의 최신 뉴스

pulisher
Jun 14, 2025

Millennium Management LLC Acquires Shares of 189,506 Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World

Jun 14, 2025
pulisher
Jun 12, 2025

Tempest Therapeutics Secures $4.1M in Direct Offering - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

SEC Form 424B5 filed by Tempest Therapeutics Inc. - Quantisnow

Jun 12, 2025
pulisher
Jun 12, 2025

Form 424B5 Tempest Therapeutics, - StreetInsider

Jun 12, 2025
pulisher
Jun 11, 2025

Tempest Therapeutics Announces $4.6 Mln Registered Direct Offering With Institutional Investor - Nasdaq

Jun 11, 2025
pulisher
Jun 11, 2025

Tempest Therapeutics (TPST) Announces New Stock Purchase Agreeme - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Tempest Therapeutics ends ATM prospectus with Jefferies By Investing.com - Investing.com Canada

Jun 11, 2025
pulisher
Jun 11, 2025

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock - The Manila Times

Jun 11, 2025
pulisher
Jun 11, 2025

Tempest Therapeutics, Inc. Announces $4.6 Million Registered Direct Offering of Common Stock - Nasdaq

Jun 11, 2025
pulisher
Jun 11, 2025

Tempest Therapeutics announces $4.6 million registered direct offering - Investing.com

Jun 11, 2025
pulisher
Jun 11, 2025

Tempest Therapeutics ends ATM prospectus with Jefferies - Investing.com

Jun 11, 2025
pulisher
Jun 11, 2025

Tempest Therapeutics Terminates ATM Prospectus Supplement Dated February 6, 2025SEC Filing - MarketScreener

Jun 11, 2025
pulisher
Jun 09, 2025

Why Circle Internet Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga

Jun 09, 2025
pulisher
Jun 09, 2025

Pre-market Movers: KLTO, TPST, PYPD, MOVE... - RTTNews

Jun 09, 2025
pulisher
Jun 06, 2025

Tempest Therapeutics Shifts Executives to Consulting Roles - TipRanks

Jun 06, 2025
pulisher
Jun 05, 2025

Tempest Therapeutics stock rises on EMA Orphan Drug Designation By Investing.com - Investing.com South Africa

Jun 05, 2025
pulisher
Jun 05, 2025

Tempest Therapeutics stock rises on EMA Orphan Drug Designation - Investing.com

Jun 05, 2025
pulisher
Jun 05, 2025

Tempest Therapeutics Says Amezalpat Gets EMA Orphan Drug Designation in Liver Cancer - marketscreener.com

Jun 05, 2025
pulisher
Jun 05, 2025

Tempest Therapeutics: European Medicines Agency Grants Orphan Drug Designation To Amezalpat - Nasdaq

Jun 05, 2025
pulisher
Jun 05, 2025

TPST Receives EMA Orphan Drug Designation for Liver Cancer Treatment | TPST Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Tempest Receives Orphan Drug Designation from the European - GlobeNewswire

Jun 05, 2025
pulisher
May 23, 2025

Tempest Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 23, 2025
pulisher
May 19, 2025

HC Wainwright Issues Optimistic Estimate for TPST Earnings - Defense World

May 19, 2025
pulisher
May 16, 2025

Tempest Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 16, 2025
pulisher
May 16, 2025

Layoff Tracker: Allogene Cuts 28% of Staff to Extend Runway, Focus on Clinical Programs - BioSpace

May 16, 2025
pulisher
May 14, 2025

TPST Highlights Promising Data for Cancer Therapy | TPST Stock N - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times

May 14, 2025
pulisher
May 13, 2025

Tempest Therapeutics Q1 Operating Income USD -10.936 Million - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Tempest Therapeutics Reports Positive Amezalpat Data and FDA Designations for Cancer Treatment Programs - Nasdaq

May 13, 2025
pulisher
May 13, 2025

FDA Grants Multiple Key Designations to Tempest Cancer Drugs as New AACR Data Shows Promise - Stock Titan

May 13, 2025
pulisher
May 11, 2025

Millendo Therapeutics, Inc. Announces Board Changes - marketscreener.com

May 11, 2025
pulisher
May 08, 2025

Cash-strapped Bay Area biotech company lays off all but 5 employees - MSN

May 08, 2025
pulisher
May 05, 2025

Tempest Therapeutics Inc expected to post a loss of $3.29 a shareEarnings Preview - TradingView

May 05, 2025
pulisher
May 04, 2025

Geode Capital Management LLC Has $296,000 Stake in Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World

May 04, 2025
pulisher
May 03, 2025

TPSTTempest Therapeutics Inc Latest Stock News & Market Updates - Stock Titan

May 03, 2025
pulisher
Apr 30, 2025

XTX Topco Ltd Has $134,000 Position in Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World

Apr 30, 2025
pulisher
Apr 29, 2025

Tempest Therapeutics regains Nasdaq compliance By Investing.com - Investing.com Canada

Apr 29, 2025
pulisher
Apr 28, 2025

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting - The Manila Times

Apr 28, 2025
pulisher
Apr 28, 2025

Tempest Therapeutics Presents Promising Amezalpat Data at 2025 AACR Annual Meeting, Supporting Novel Cancer Treatment Mechanism - Nasdaq

Apr 28, 2025
pulisher
Apr 28, 2025

Tempest Presents New Amezalpat MOA Data Reinforcing Its - GlobeNewswire

Apr 28, 2025
pulisher
Apr 28, 2025

Breakthrough: New Cancer Drug Amezalpat Demonstrates Dual Anti-Cancer Mechanism in Multiple Tumors - Stock Titan

Apr 28, 2025
pulisher
Apr 28, 2025

Tempest Therapeutics regains Nasdaq compliance - Investing.com

Apr 28, 2025
pulisher
Apr 27, 2025

Market Recap Check: Tempest Therapeutics Inc (TPST)’s Negative Finish at 0.61, Up/Down -14.53 - DWinneX

Apr 27, 2025
pulisher
Apr 24, 2025

Struggling Bay Area biotech company, once worth $1B, lays off all but 5 workers - SFGATE

Apr 24, 2025
pulisher
Apr 22, 2025

Tempest Therapeutics - The Pharma Letter

Apr 22, 2025
pulisher
Apr 21, 2025

Tempest Therapeutics stock rises on FDA Orphan Drug Designation By Investing.com - Investing.com Nigeria

Apr 21, 2025
pulisher
Apr 21, 2025

Tempest Therapeutics stock rises on FDA Orphan Drug Designation - Investing.com Australia

Apr 21, 2025
pulisher
Apr 21, 2025

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP - The Manila Times

Apr 21, 2025

Tempest Therapeutics Inc (TPST) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Tempest Therapeutics Inc 주식 (TPST) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Versant Venture Capital VI, L.
10% Owner
Aug 08 '24
Sale
1.35
400,000
540,040
597,940
Versant Venture Capital VI, L.
10% Owner
Aug 12 '24
Sale
1.10
387,999
426,993
209,941
$20.42
price down icon 1.37%
$35.45
price up icon 0.65%
$21.06
price down icon 1.92%
$101.83
price down icon 0.41%
$105.86
price down icon 0.39%
biotechnology ONC
$244.00
price down icon 3.69%
자본화:     |  볼륨(24시간):